>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Anisomycin 茴香霉素; Flagecidin; Wuningmeisu C

Anisomycin 是一种有效的蛋白质合成抑制剂，通过抑制肽基转移酶 80 核糖体系统干扰蛋白质和 DNA 合成。Anisomycin 是一种 JNK 激活剂，可增强磷酸化 JNK 。Anisomycin 是一种细菌抗生素。

货号：
TK0284
规格：

1mg

5mg

10mg

50mg
价格：
￥0.00

产品参数

CAS No.	22862-76-6
生物活性	Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin is a JNK activator, which increases phospho-JNK. Anisomycin is a bacterial antibiotic.
分子式	C14H19NO4
分子量	265.31
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	Powder -20°C 3 years
溶解性数据	DMSO : ≥ 50 mg/mL (188.46 mM) H2O : 4 mg/mL (15.08 mM; ultrasonic and warming and heat to 60°C)
体内研究	Anisomycin (60 mg/kg; for 4-week continuous intravenous administration) significantly decreases mouse body weight in a dose-related manner, compared with the control group. Anisomycin (15 mg/kg; for 4-week continuous intravenous administration) slightly and transiently decreases the mouse body weight. There is no significant difference of the mouse body weight in 5 mg/kg group.
体外研究	To examine whether JNK has a core role in colistin-induced neurotoxicity in PC-12 cells, an SP600125 (a highly selective inhibitor of JNK) and Anisomycin (a potent activator) are used in this study. In order to select an appropriate concentration, PC-12 cells are treated with a range of SP600125 (0-80 μM) and Anisomycin (0-20 μM) respectively for 24 h. The results show that the cells viability significantly decreases by SP600125 treatment in a concentration-dependent manner, observed at the concentrations greater than 20 μM (p<0.01). Similarly the cells viability is inhibited by Anisomycin treatment (≥8 μM) (p<0.05) .
文献	•J Exp Clin Cancer Res. 2020 Feb 5;39(1):29. •J Hazard Mater. 2020 Nov 15;399:122809. •Diabetes. 2021 Oct 21;db210240. •Cell Rep. 2021 Jul 20;36(3):109398. •Cell Death Dis. 2021 Jan 11;12(1):63. •J Inflamm Res. 2021 Sep 16;14:4669-4686. •Oxid Med Cell Longev. 23 Sep 2021. •Anim Nutr. 15 September 2021. •Mol Med. 2021 May 30;27(1):53. •Acta Pharmacol Sin. 2020 Apr;41(4):561-571. •Front Mol Neurosci. 2017 Aug 28;10:269. •Reprod Biol Endocrinol. 2020 Oct 12;18(1):100. •Chem Biol Interact. 2017 Nov 1;277:62-73. •Life Sci. 2021 Mar 1;119304. •Int Immunopharmacol. 2020 Nov;88:106949. •J Immunol Res. 2020 Feb 10;2020:6457879. •Eur J Pharmacol. 2021 Oct 5;908:174356. •Eur J Pharmacol. 2018 Sep 5;834:295-304. •Sci Rep. 2020 Oct 22;10(1):18119. •Sci Rep. 2018 Apr 23;8(1):6379. •Sci Rep. 2017 Oct 19;7(1):13571. •Am J Physiol Cell Physiol. 2018 Aug 1;315(2):C225-C235. •Am J Transl Res. 2019 Jun 15;11(6):3862-3878. •Biosci Rep. 2020 May 29;40(5):BSR20193256. •Biochem Biophys Res Commun. 2018 Sep 5;503(2):467-473. •Biochem Biophys Res Commun. 2018 May 23;499(4):743-750. •Infect Genet Evol. 2021 Nov 23;105158. •Comp Biochem Physiol C Toxicol Pharmacol. 2021 Apr 19;109053. •Mol Med Rep. 2019 Jan;19(1):41-50. •FEBS Open Bio. 2020 Apr;10(4):593-606. •Exp Ther Med. 2020 Aug;20(2):926-932. •Int J Lab Hematol. 2021 Mar 8.
纯度及产品资料	98%

推荐产品